2025 Q2 -tulosraportti
221 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·33 min sittenQ2 is now underway, a quarter that for Circio shareholders can go down in history and that they will never forget. All of 2026 will offer regular news and updates on the potential of the CircVec platform also via all collaboration projects. Let's concentrate this on Circio's internal status now in Q2 and the next 2-3 months and why this could generate significant further share price appreciation. This must be based on Circio's presentations 28. Aug 25, 24. Nov 25 and 26. Feb 26. In addition, news and small tidbits have come via a number of media activities this winter. It can be stated that the study projects in the various projects have a duration of approx 2-3 months and that since then studies have been done with circVec versions 3.0, 3.2 and 4.0. This has led to double or more studies both to get results with the newest version circVec and to quality assure the results. This probably means that the company is sitting on a significant amount of results and data long before they are published. We now know that they have submitted 2 Abstracts that are approved for oral and poster presentation at ASGCT in May. These are important data that have not been published. On 13. April we will know what the topics are. Studies in "muscle" were ongoing in v 3.2 in Aug 25. In February, it is not part of Circio's internal projects. In Aug 25 it was stated that Entos proceeded with its projects and financed them. Entos has a project in muscular dystrophy with the Durchenne association in the USA. No info has come from the Entos collaboration yet.
·17 min sittenYes, that was a good summary of the situation now and going forward! Thanks! Do you have an opinion on when the first license money must start rolling in? Latest autumn/winter 2026? For the stock to be able to take the 'next' step?
·1 t sitten · MuokattuWe have seen an increase of more than 10x in the share price in a relatively short time. What is driving this increase and can it continue? I have made an analysis of the DNA in the Circio case: https://drive.google.com/file/d/11qbKJVOa3dQuyVaElSe2UBJlaGPTF2T5/view?usp=sharing Circio is not a classic biotech-case (like e.g. Curasight). It is a re-rating/timing-case. The market prices in success long before it is proven. This effectively means that the share price can rise even more towards the crucial data point. But there's a downside: The higher the share price goes, the harder the fall will be if CAR-T disappoints The next few weeks are not about truth, but about expectations. And that's exactly where the money is made… or lost (big time!)·25 min sittenOffhand, it feels more like AI has done an analysis for you? CircVec, then?
·2 t sittenPeople waited in vain for a dip here haha Nice work and congratulations to you long-term holders.·2 t sittenThanks Bagnis, nice you're checking in, the only ”problem” for us long-term holders is that it's hard to buy more on the little dip that never comes…
·3 t sittenSaw the Japanese released this today. Does anyone have access to the full article via work/university? https://unitedimmunity.co.jp/en/news/detail/united-immunity-publishes-an-article-in-the-journal-pharmacia
·42 min sittenI cannot access the full article. I have been trying for a long time now. But based on the abstract, one can at least understand that "delivery" of RNA medicines to the correct cells is a challenge, and that this is obviously something United Immunity is working on right now. We also know that United Immunity has a collaboration agreement with Circio. So if Circio manages to deliver a better solution, we will have a historical winner in the long run. It is important to mention that the study probably only shows a mechanical and preclinical understanding of how the delivery and application of RNA are affected by endosomes and lysosomes. More research is needed, and preferably clinical.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
221 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·33 min sittenQ2 is now underway, a quarter that for Circio shareholders can go down in history and that they will never forget. All of 2026 will offer regular news and updates on the potential of the CircVec platform also via all collaboration projects. Let's concentrate this on Circio's internal status now in Q2 and the next 2-3 months and why this could generate significant further share price appreciation. This must be based on Circio's presentations 28. Aug 25, 24. Nov 25 and 26. Feb 26. In addition, news and small tidbits have come via a number of media activities this winter. It can be stated that the study projects in the various projects have a duration of approx 2-3 months and that since then studies have been done with circVec versions 3.0, 3.2 and 4.0. This has led to double or more studies both to get results with the newest version circVec and to quality assure the results. This probably means that the company is sitting on a significant amount of results and data long before they are published. We now know that they have submitted 2 Abstracts that are approved for oral and poster presentation at ASGCT in May. These are important data that have not been published. On 13. April we will know what the topics are. Studies in "muscle" were ongoing in v 3.2 in Aug 25. In February, it is not part of Circio's internal projects. In Aug 25 it was stated that Entos proceeded with its projects and financed them. Entos has a project in muscular dystrophy with the Durchenne association in the USA. No info has come from the Entos collaboration yet.·17 min sittenYes, that was a good summary of the situation now and going forward! Thanks! Do you have an opinion on when the first license money must start rolling in? Latest autumn/winter 2026? For the stock to be able to take the 'next' step?
- ·1 t sitten · MuokattuWe have seen an increase of more than 10x in the share price in a relatively short time. What is driving this increase and can it continue? I have made an analysis of the DNA in the Circio case: https://drive.google.com/file/d/11qbKJVOa3dQuyVaElSe2UBJlaGPTF2T5/view?usp=sharing Circio is not a classic biotech-case (like e.g. Curasight). It is a re-rating/timing-case. The market prices in success long before it is proven. This effectively means that the share price can rise even more towards the crucial data point. But there's a downside: The higher the share price goes, the harder the fall will be if CAR-T disappoints The next few weeks are not about truth, but about expectations. And that's exactly where the money is made… or lost (big time!)·25 min sittenOffhand, it feels more like AI has done an analysis for you? CircVec, then?
- ·2 t sittenPeople waited in vain for a dip here haha Nice work and congratulations to you long-term holders.·2 t sittenThanks Bagnis, nice you're checking in, the only ”problem” for us long-term holders is that it's hard to buy more on the little dip that never comes…
- ·3 t sittenSaw the Japanese released this today. Does anyone have access to the full article via work/university? https://unitedimmunity.co.jp/en/news/detail/united-immunity-publishes-an-article-in-the-journal-pharmacia·42 min sittenI cannot access the full article. I have been trying for a long time now. But based on the abstract, one can at least understand that "delivery" of RNA medicines to the correct cells is a challenge, and that this is obviously something United Immunity is working on right now. We also know that United Immunity has a collaboration agreement with Circio. So if Circio manages to deliver a better solution, we will have a historical winner in the long run. It is important to mention that the study probably only shows a mechanical and preclinical understanding of how the delivery and application of RNA are affected by endosomes and lysosomes. More research is needed, and preferably clinical.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
221 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·33 min sittenQ2 is now underway, a quarter that for Circio shareholders can go down in history and that they will never forget. All of 2026 will offer regular news and updates on the potential of the CircVec platform also via all collaboration projects. Let's concentrate this on Circio's internal status now in Q2 and the next 2-3 months and why this could generate significant further share price appreciation. This must be based on Circio's presentations 28. Aug 25, 24. Nov 25 and 26. Feb 26. In addition, news and small tidbits have come via a number of media activities this winter. It can be stated that the study projects in the various projects have a duration of approx 2-3 months and that since then studies have been done with circVec versions 3.0, 3.2 and 4.0. This has led to double or more studies both to get results with the newest version circVec and to quality assure the results. This probably means that the company is sitting on a significant amount of results and data long before they are published. We now know that they have submitted 2 Abstracts that are approved for oral and poster presentation at ASGCT in May. These are important data that have not been published. On 13. April we will know what the topics are. Studies in "muscle" were ongoing in v 3.2 in Aug 25. In February, it is not part of Circio's internal projects. In Aug 25 it was stated that Entos proceeded with its projects and financed them. Entos has a project in muscular dystrophy with the Durchenne association in the USA. No info has come from the Entos collaboration yet.·17 min sittenYes, that was a good summary of the situation now and going forward! Thanks! Do you have an opinion on when the first license money must start rolling in? Latest autumn/winter 2026? For the stock to be able to take the 'next' step?
- ·1 t sitten · MuokattuWe have seen an increase of more than 10x in the share price in a relatively short time. What is driving this increase and can it continue? I have made an analysis of the DNA in the Circio case: https://drive.google.com/file/d/11qbKJVOa3dQuyVaElSe2UBJlaGPTF2T5/view?usp=sharing Circio is not a classic biotech-case (like e.g. Curasight). It is a re-rating/timing-case. The market prices in success long before it is proven. This effectively means that the share price can rise even more towards the crucial data point. But there's a downside: The higher the share price goes, the harder the fall will be if CAR-T disappoints The next few weeks are not about truth, but about expectations. And that's exactly where the money is made… or lost (big time!)·25 min sittenOffhand, it feels more like AI has done an analysis for you? CircVec, then?
- ·2 t sittenPeople waited in vain for a dip here haha Nice work and congratulations to you long-term holders.·2 t sittenThanks Bagnis, nice you're checking in, the only ”problem” for us long-term holders is that it's hard to buy more on the little dip that never comes…
- ·3 t sittenSaw the Japanese released this today. Does anyone have access to the full article via work/university? https://unitedimmunity.co.jp/en/news/detail/united-immunity-publishes-an-article-in-the-journal-pharmacia·42 min sittenI cannot access the full article. I have been trying for a long time now. But based on the abstract, one can at least understand that "delivery" of RNA medicines to the correct cells is a challenge, and that this is obviously something United Immunity is working on right now. We also know that United Immunity has a collaboration agreement with Circio. So if Circio manages to deliver a better solution, we will have a historical winner in the long run. It is important to mention that the study probably only shows a mechanical and preclinical understanding of how the delivery and application of RNA are affected by endosomes and lysosomes. More research is needed, and preferably clinical.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt